GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » ROC (Joel Greenblatt) %

PuraPharm (HKSE:01498) ROC (Joel Greenblatt) % : -19.89% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. PuraPharm's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -19.89%.

The historical rank and industry rank for PuraPharm's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:01498' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -32.1   Med: 6.17   Max: 25.14
Current: -13.81

During the past 10 years, PuraPharm's highest ROC (Joel Greenblatt) % was 25.14%. The lowest was -32.10%. And the median was 6.17%.

HKSE:01498's ROC (Joel Greenblatt) % is ranked worse than
69.58% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 7.85 vs HKSE:01498: -13.81

PuraPharm's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


PuraPharm ROC (Joel Greenblatt) % Historical Data

The historical data trend for PuraPharm's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm ROC (Joel Greenblatt) % Chart

PuraPharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.10 11.38 -13.37 -14.61 -14.00

PuraPharm Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.68 -5.99 -23.69 -8.10 -19.89

Competitive Comparison of PuraPharm's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where PuraPharm's ROC (Joel Greenblatt) % falls into.



PuraPharm ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(127.422 + 203.951 + 80.517) - (258.661 + 0 + 0.173)
=153.056

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(132.273 + 175.597 + 27.621) - (248.924 + 0 + 0.17000000000007)
=86.397

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of PuraPharm for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-103.478/( ( (403.904 + max(153.056, 0)) + (396.905 + max(86.397, 0)) )/ 2 )
=-103.478/( ( 556.96 + 483.302 )/ 2 )
=-103.478/520.131
=-19.89 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PuraPharm  (HKSE:01498) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


PuraPharm ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of PuraPharm's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm (HKSE:01498) Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines